METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot every 12 weeks aims to control advanced prostate cancer
Disease control Recruiting nowThis study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, to lower testosterone in men with advanced prostate cancer. The goal is to find a safe dose and see if it works alone or with another drug, enzalutamide. About 174 men whose cance…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 17, 2026 09:09 UTC
-
New drug combo aims to slow advanced prostate cancer
Disease control Recruiting nowThis study tests whether adding the experimental drug saruparib to standard hormone therapy can slow the growth of metastatic prostate cancer that still responds to hormone treatment. About 1,800 men with a specific genetic marker (HRRm) or without it will be randomly assigned to…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 07, 2026 18:39 UTC